Preclinical potency and biodistribution studies of an AAV 5 vector expressing human interferon-β (ART-I02) for local treatment of patients with rheumatoid arthritis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Aalbers, Caroline J ^a,b   Bevaart, Lisette ^a,b   Loiler, Scott ^a,b,g   De Cortie, Karin ^a,b,h   Wright, J Fraser ^c,d   Mingozzi, Federico ^e,f   Tak, Paul P ^a,b,i   Vervoordeldonk, Margriet J ^a,b  

^a Arthrogen BV   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SORBONNE UNIVERSITÉ   (France)

^f GÉNÉTHON   (France)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h TNO   (Netherlands)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ART 102; BETA INTERFERON; DNA; METHOTREXATE; UNCLASSIFIED DRUG; VIRUS VECTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNTHETIC DNA;

ADENO ASSOCIATED VIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RABBIT; RAT; RHESUS MONKEY; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; TRANSGENE; ADMINISTRATION AND DOSAGE; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DBA MOUSE; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; GERMFREE ANIMAL; INTRAARTICULAR DRUG ADMINISTRATION; LEWIS RAT; MOUSE; PHARMACOKINETICS; PROMOTER REGION; SYNOVIUM; THERAPEUTIC USE; TISSUE DISTRIBUTION; VIROLOGY;

ANIMALIA; MACACA MULATTA; MUS; ORYCTOLAGUS CUNICULUS; RATTUS; RODENTIA;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; DEPENDOVIRUS; GENE EXPRESSION; GENES, SYNTHETIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRA-ARTICULAR; INTERFERON-BETA; MACACA MULATTA; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RABBITS; RATS; RATS, INBRED LEW; SPECIFIC PATHOGEN-FREE ORGANISMS; SYNOVIAL MEMBRANE; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

EID: 84939246896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130612     Document Type: Article

References (38)

1. Tak PP. IFN-beta in rheumatoid arthritis. Front Biosci. 2004; 9: 3242-3247. PMID: 15353352
2. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2004; 6: R239-R249. PMID: 15142270
3. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999; 42: 90-99. PMID: 9920019
4. Tak PP, Hart BA, Kraan MC, Jonker M, Smeets TJ, Breedveld FC. The effects of interferon beta treatment on arthritis. Rheumatology (Oxford). 1999; 38: 362-369. PMID: 10378715
5. Van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis. 2005; 64: 64-69. PMID: 15242865
6. Adriaansen J, Kuhlman RR, van Holten J, Kaynor C, Vervoordeldonk MJ, Tak PP. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther. 2006; 17: 985-996. PMID: 16984225
7. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A. 1995; 92: 5719-5723. PMID: 7777575
8. Adriaansen J, Tas SW, Klarenbeek PL, Bakker AC, Apparailly F, Firestein GS, et al. Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis. 2005; 64: 1677-1684. PMID: 15878906
9. Apparailly F, Khoury M, Vervoordeldonk MJ, Adriaansen J, Gicquel E, Perez N, et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther. 2005; 16: 426-434. PMID: 15871674
10. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21: 704-712. doi: 10.1089/hum.2009.182 PMID: 20095819
11. Mingozzi F, Chen Y, Edmonson SC, Zhou S, Thurlings RM, Tak PP, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 2013; 20:417-424. doi: 10.1038/gt.2012.55 PMID: 22786533
12. Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J Gen Virol. 2007; 88: 1717-1721. PMID: 17485531
13. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood. 2007; 109: 1414-1421. PMID: 17090654
14. Paneda A, Vanrell L, Mauleon I, Crettaz JS, Berraondo P, Timmermans EJ, et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther. 2009; 20: 908-917. doi: 10.1089/hum.2009.031 PMID: 19419275
15. Favaro P, Finn JD, Siner JI, Wright JF, High KA, Arruda VR. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther. 2011; 22: 843-852. doi: 10.1089/hum.2010.155 PMID: 21126217
16. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998; 5: 938-945. PMID: 9813665
17. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002; 99: 11854-11859. PMID: 12192090
18. van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis. 2011; 70: 423-427. doi: 10.1136/ard.2010.139550 PMID: 21109518
19. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum. 2001; 44: 1897-1907. PMID: 11508443
20. Ruijter JM, Thygesen HH, Schoneveld OJ, Das AT, Berkhout B, Lamers WH. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology. 2006; 3: 2. 1742-1746. PMID: 16398936
21. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005; 5: 285-297. PMID: 15975006
22. Yan Z, Zak R, Zhang Y, Ding W, Godwin S, Munson K, et al. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol. 2004; 78: 2863-2874. PMID: 14990705
23. Yan Z, Lei-Butters DC, Zhang Y, Zak R, Engelhardt JF. Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum Gene Ther. 2007; 18: 81-87. PMID: 17181493
24. Zhang T, Hu J, Ding W, Wang X. Doxorubicin augments rAAV-2 transduction in rat neuronal cells. Neurochem Int. 2009; 55: 521-528. doi: 10.1016/j.neuint.2009.05.005 PMID: 19450628
25. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol. 1994; 68: 8282-8287. PMID: 7966621
26. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004; 50: 1370-1382. PMID: 15146406
27. Bologna C, Edno L, Anaya JM, Canovas F, Vanden Berghe M, Jorgensen C, et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum. 1994; 37: 1770-1773. PMID: 7986223
28. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 2010; 62: 2192-2205. doi: 10.1002/art.27503 PMID: 20506322
29. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol. 1999; 163: 2202-2208. PMID: 10438962
30. Lechman ER, Keravala A, Nash J, Kim SH, Mi Z, Robbins PD. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther. 2003; 10: 2029-2035. PMID: 14566362
31. Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009; 15: 1414-1420. doi: 10.1038/nm.2050 PMID: 19898488
32. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A. 2005; 102: 8698-8703. PMID: 15939878
33. Gouze E, Gouze JN, Palmer GD, Pilapil C, Evans CH, Ghivizzani SC. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther. 2007; 15: 1114-1120. PMID: 17440444
34. Watson RS, Broome TA, Levings PP, Rice BL, Kay JD, Smith AD, et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 2013; 20: 670-677. doi: 10.1038/gt.2012.81 PMID: 23151520
35. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011; 13 Suppl 1: S5. 1478-6354-13-S1-S5. doi: 10.1186/1478-6354-13-S1-S5 PMID: 21624184
36. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008; 16: 1073-1080. doi: 10.1038/mt.2008.76 PMID: 18414476
37. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009; 113: 797-806. doi: 10.1182/blood-2008-10-181479 PMID: 18957684
38. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011; 19: 876-885. doi: 10.1038/mt.2010.274 PMID: 21245849